Kamada (KMDA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.16
- Estimate
- $0.11
- Surprise
- +42.2%
- Score at report (before → after)
- 5.6 → 5.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Kamada (KMDA) beat the $0.11 estimate with diluted EPS of $0.16 — a large 42.2% upside surprise. TrendMatrix's engine moved from Sell (5.6/10) to Hold at 5.9/10 after the report.
Coverage in the report window
- Kamada Announces CFO Chaime Orlev To Depart Effective December 31 To Pursue Other Opportunities; Successor Search Underw — benzinga, 2026-08-12
- Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est — benzinga, 2026-08-12
- Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates KMDA Sell at 5.8/10.
1 of the last 4 quarters beat the estimate; this quarter's +42.2% surprise compares with a -5.5% four-quarter average. Next scheduled report: 2026-11-09.
What supports the rating
- Attractive valuation
- Positive insider activity
What argues against it
- Consecutive earnings misses (2)
- Weak growth
- News modifier -1: HOLD_IF_HOLDING → SELL_IF_HOLDING
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.24
- Price target
- $11.47
- Stop
- $7.74
- Upside to target
- +39.2%
- Reward-to-risk
- 2.6:1
The stock trades at 21.1× trailing but 13.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
KMDA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $475.4M
- P/E (fwd)
- 13.8
- P/E (ttm)
- 21.1
- 52-week range
- $6.50–$9.35
- Off 52-week high
- 11.9%
- RSI (14)
- 73
- Volume vs avg
- 0.83×
- Score today
- 5.8/10